Jefferies Reaffirms Their Buy Rating on Progenics

By Carrie Williams

Jefferies analyst Biren Amin reiterated a Buy rating on Progenics (NASDAQ: PGNX) today and set a price target of $12. The company’s shares opened today at $6.99.

According to, Amin is a 4-star analyst with an average return of 3.2% and a 47.5% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Stemline Therapeutics Inc, and Lion Biotechnologies Inc.

Progenics has an analyst consensus of Moderate Buy, with a price target consensus of $13.

The company has a one year high of $11.72 and a one year low of $4. Currently, Progenics has an average volume of 1.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipelines are therapeutic agents, imaging agents for prostate cancer, and imaging analysis tools. The company was founded by Paul J. Maddon in 1986 and is headquartered in Tarrytown, NY.